Orphanet Journal of Rare Diseases · 2022 · 42 citations · 28 references
MedicineChild HealthPediatricsPalliative CarePediatric EndocrinologyPediatric NephrologyDisorders Of Calcium MetabolismElectrolyte DisordersHealth-related Quality Of LifeHealth-related Quality Of Life MeasurementHuman HealthQuality Of LifeActivitiesActivities ParticipationEarly DiagnosisEuroqol Five DimensionsHereditary Hypophosphatemic DisordersHypophosphatemia TreatmentPediatric Quality Of LifePsychosocial Support During Diagnosis
BACKGROUND: Health-related quality of life (HRQoL) of patients with X-linked hypophosphatemia (XLH) is lower than that of both the general population and the patients with other chronic diseases, mainly due to diagnostic delay, treatment difficulties, poor psychosocial support, and problems with social integration. Early diagnosis and optimal treatment are paramount to control the disease in patients with XLH, avoid complications, and maintain or improve their HRQoL. We, therefore, analyzed the HRQoL of pediatric and adult patients with XLH treated with conventional therapy in Spain. RESULTS: We used several versions of the EuroQol-5 dimensions (EQ-5D) instrument according to the age of patients with XLH. Then we compared the HRQoL of patients to that of the general Spanish population. Children with XLH (n = 21) had moderate problems in walking about (61.9%), washing or dressing themselves (9.52%), and performing their usual activities (33.33%). They also felt moderate pain or discomfort (61.9%) and were moderately anxious or depressed (23.81%). Adults with XLH (n = 29) had lower HRQoL, with problems in walking (93%, with 3.45% unable to walk independently), some level of pain (86%, with 3.45% experiencing extreme pain), problems with their usual activities (80%) and self-care (> 50%), and reported symptoms of anxiety and/or depression (65%). There were important differences with the general Spanish population. CONCLUSIONS: XLH impacts negatively on physical functioning and HRQoL of patients. In Spanish patients with XLH, the HRQoL was reduced despite conventional treatment, clearly indicating the need to improve the therapeutic approach to this disorder.
28
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Thomas O. Carpenter, Michael P. Whyte, Erik A. Imel et al. · New England Journal of Medicine · 2018 · 473 citations · Full text
Medicine, Endocrinology, Nephrology +17
Karl Insogna, Karine Briot, Erik A. Imel et al. · Journal of Bone and Mineral Research · 2018 · 340 citations · Full text